The proposed impact assessment will form a good foundation for revision of the general pharmaceutical legislation. We would however emphasise the importance of devoting sufficient attention to the proper functioning of the legislation regarding off-patent medicinal products. There are substantial differences in access, affordability, sustainability and security of supply for off patented and patented medicines.
NMA
Norwegian Medicines Agency
Public authority · Norway · EU Transparency Register 974 761 122not in register snapshot
This register number is the organization’s own declaration on its submission. It is not in the 2 Sept 2026 snapshot of the EU Transparency Register, so we neither link to it nor use it to identify this organization.
3
positions filed
in the 583 files tracked
3
legislative files
of 583 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Track Norwegian in PolicySpeak: request access →
Work at Norwegian Medicines Agency? so we know who speaks for it.
Their record over time
Norwegian Medicines Agency filed 3 positions between 14 Dec 2020 and 6 Jun 2023, across 3 of the 583 legislative files tracked here.
2020 · 1 filed2021 · 1 filed2023 · 1 filed
What they argued
Comments from the Norwegian Medicines Agency on the Inception Impact Assessment for the revision of the Union legislation on blood, tissues and cells The Norwegian Medicines Agency (NOMA) welcomes the possibility to comment on the Commission’s Inception Impact Assessment for the revision of the blood, cell and tissue (BTC) legislation. NOMA acknowledges the need for revision of the BTC legislation.
Designer precursors is a problem that the current legislation does not fully cover, so a targeted regulatory approach where the issue of designer precursors is included, is very favourable. Policy options 3 and 4 would create maximum impact. Norway has generic scheduling in the national narcotics regulation and considering a regulatory approach on EU-level where the same is done for precursors is very positive.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Norwegian Medicines Agency next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
Showing 5 of 29.
Is this your organization?
Everything on this page comes from Norwegian Medicines Agency’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.